Reduced oral itraconazole bioavailability by antacid suspension

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 3, 2005, Pages 201-206

  Lohitnavy, Manupat ^a,b   Lohitnavy, O ^a   Thangkeattiyanon, O ^a   Srichai, W ^a  

^a NARESUAN UNIVERSITY   (Thailand)

^b Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Antacid; Bioavailability; Drug absorption; Drug interaction; Itraconazole; Pharmacokinetics

Indexed keywords

ANTACID AGENT; ITRACONAZOLE; SPORAL; ALUMINUM HYDROXIDE; ALUMINUM MAGNESIUM HYDROXIDE; ANTIFUNGAL AGENT; MAGNESIUM HYDROXIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SUSPENSION; VOLUNTEER; ADOLESCENT; BIOAVAILABILITY; DRUG ANTAGONISM; DRUG COMBINATION; INTESTINE ABSORPTION; MIDDLE AGED;

ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTACIDS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG ANTAGONISM; DRUG COMBINATIONS; HUMANS; INTESTINAL ABSORPTION; ITRACONAZOLE; MAGNESIUM HYDROXIDE; MALE; MIDDLE AGED; SUSPENSIONS;

EID: 23844437130     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00632.x     Document Type: Article

References (27)

1. Boogaerts M, Maertens J (2001) Clinical experience with itraconazole in systemic fungal infections. Drugs, 61 (Suppl. 1), 39-47.
2. De Beule K, Van Gestel J (2001) Pharmacology of itraconazole. Drugs, 61 (Suppl. 1), 27-37.
3. Pierard GE, Arrese JE, Pierard-Franchimont C (2000) Itraconazole. Expert Opinion on Pharmacotherapy, 1, 287-304.
4. Jain S, Sehgal VN (2001) Itraconazole: an effective oral antifungal for onychomycosis. International Journal of Dermatology, 40, 1-5.
5. Haria M, Bryson HM, Goa KL (1996) Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs, 51, 585-620.
6. Boyle BM, McCann SR (2000) The use of itraconazole as prophylaxis against invasive fungal infection in blood and marrow transplant recipients. Transplant Infectious Disease, 2, 72-79.
7. Marty F, Mylonakis E (2002) Antifungal use in HIV infection. Expert Opinion on Pharmacotherapy, 3, 91-102.
8. Vazquez JA (2000) Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clinical Trials, 1, 47-59.
9. Boger RH (2001) Drug interactions of the statins and consequences for drug selection. International Journal of Clinical Pharmacology and Therapeutics, 39, 369-382.
10. Jaruratanasirikul S, Sriwiriyajan S (1998) Effect of omeprazole on the pharmacokinetics of itraconazole. European Journal of Clinical Pharmacology, 54, 159-161.
11. Jaruratanasirikul S, Sriwiriyajan S (1998) Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. European Journal of Clinical Pharmacology, 54, 155-158.
12. Barone JA, Moskovitz BL, Guarnieri J et al. (1998) Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy, 18, 295-301.
13. Van de Velde VJ, Van Peer AP, Heykants JJ et al. (1996) Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy, 16, 424-428.
14. Jaruratanasirikul S, Kleepkaew A (1997) Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. European Journal of Clinical Pharmacology, 52, 235-237.
15. Shelton MJ, O'Donnell AM, Morse GD (1992) Didanosine. Annals of Pharmacotherapy, 26, 660-670.
16. Damle B, Hess H, Kaul S et al. (2002) Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric coated bead formulation with either itraconazole or fluconazole. Biopharmaceutics and Drug Disposition, 23, 59-66.
17. Begg EJ, Barclay ML, Kirkpatrick CJ (1999) The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 47, 23-30.
18. Negro RD (1998) Pharmacokinetic drug interactions with anti-ulcer drugs. Clinical Pharmacokinetics, 35, 135-150.
19. Honig PK, Gillespie BK (1995) Drug interaction between prescribed and over-the-counter medication. Drug Safety, 13, 296-303.
20. Rifai N, Sakamoto M, Platt O et al. (1995) A high-performance liquid chromatographic assay for the determination of itraconazole concentration using solid-phase extraction and small sample volume. Therapeutic Drug Monitoring, 17, 522-525.
21. Olling M, Mensinga TT, Barends DM et al. (1999) Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharmaceutics and Drug Disposition, 20, 19-28.
22. Lohitnavy M, Lohitnavy O, Wittaya-areekul S et al. (2003) Average bioequivalence of clarithromycin immediate-released tablet formulations in healthy male volunteers. Drug Development and Industrial Pharmacy, 29, 653-659.
23. Lohitnavy M, Lohitnavy O, Sareekan K et al. (2003) Average bioequivalence study of clarithromycin tablets in healthy male volunteers. Journal of Clinical Pharmacy and Therapeutics, 28, 187-190.
24. Lohitnavy O, Lohitnavy M, Sareekan K et al. (2003) Average bioequivalence of generic clarithromycin tablets in healthy Thai male volunteers. Biopharmaceutics and Drug Disposition, 24, 229-231.
25. Lohitnavy M, Lohitnavy O, Chaijittiprasert K, Taytiwat P, Polnok S., Sareekan K (2003) Pharmacokinetic and bioequivalence studies of generic clarithromycin tablets in healthy male volunteers. Pharmazie, 58, 72-73.
26. Semino G, Lilly P, Andersen ME (1997) A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride. Toxicology, 117, 25-33.
27. Bungay PM, Dedrick RL, Mattews HB (1981) Enteric transport of chlordecone (Kepone) in the rat. Journal of Pharmacokinetics and Biopharmaceutics, 9, 309-341.